Analyst firms · Raymond James · ADMA

Raymond James ADMA price target and rating history

ADMA Biologics Inc (ADMA) · Health Care

Raymond James rates ADMA Biologics Inc (ADMA) Outperform with a $21 price target, as of its latest action on Jun 10, 2026. It has published 4 rating actions on ADMA since October 2021, including 1 upgrade and 0 downgrades.

Current rating
Outperform
Price target
$21
Median target, all firms
Too few
Actions on ADMA
4

Raymond James price target on ADMA

$21$13$520222023202420252026
Raymond James price target on ADMA, each point a stated target, October 2021 to June 2026.

Every Raymond James rating on ADMA

How other firms rate ADMA

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
Raymond JamesOutperform$21Jun 10, 2026
Canaccord GenuityBuy$21Apr 21, 2026
Cantor FitzgeraldNeutralMar 26, 2026

Questions about Raymond James and ADMA

What is Raymond James's price target for ADMA?
Raymond James's latest stated price target for ADMA Biologics Inc (ADMA) is $21, from its action on Jun 10, 2026.
What is Raymond James's rating on ADMA?
Raymond James rates ADMA Outperform, a bullish rating, as of Jun 10, 2026.
When did Raymond James last change its view on ADMA?
On Jun 10, 2026, Raymond James resumes coverage at Outperform, price target $21.

All Raymond James ratingsADMA news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.